Davis Polk advised the sales agents in connection with certain amendments of the SEC-registered at-the-market offering program by Millendo Therapeutics, Inc. of up to $50 million gross sales price of its common stock. The common stock is listed on the Nasdaq Global Select Market under the symbol “MLND.”
Millendo is focused on developing novel treatments for endocrine diseases. Its mission is to build a leading endocrine company that creates distinct and transformative treatments for a wide range of endocrine diseases where there is a significant unmet medical need. It is currently advancing two product candidates: livoletide (AZP-531) and nevanimibe (ATR-101). Livoletide is being developed as a potential treatment for Prader-Willi syndrome while nevanimibe is in development for the treatment of two different orphan adrenal diseases: classic congenital adrenal hyperplasia (CAH) and endogenous Cushing’s syndrome (CS).
The Davis Polk capital markets team included partner Deanna L. Kirkpatrick and associate Yoojin Nairn-Kim. All members of the Davis Polk team are based in the New York office.